Ivacaftor

• A low-intervention prospective-retrospective study to evaluate the pharmacokinetics of elexacaftor/tezacaftor/ivacaftor combination in a Cys… Pending
  2024-518785-28-00 Phase IV 1 country IRCCS Istituto Giannina Gaslini
• Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis Subjects 1 Through 11 Years of Age Recruiting
  2024-513754-29-00 Phase III 7 countries Vertex Pharmaceuticals Inc.
• Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Subjects 12 Months of Age and Older Ended
  2023-509563-24-00 Phase III 3 countries Vertex Pharmaceuticals Inc.
• Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor Long-term Safety and Efficacy in Subjects Without F508del Ended
  2024-515637-14-00 Phase III 13 countries Vertex Pharmaceuticals Inc.
• A Phase 1/2 Study of VX-522 in Subjects with Cystic Fibrosis Ended
  2023-504786-23-00 Phase I (FiH) 6 countries Vertex Pharmaceuticals Inc.
• A Phase 1/2, Multicenter Study Evaluating the Safety, Tolerability, and Biodistribution of RCT2100 with Single-Ascending Doses in Healthy Pa… Ended
  2024-512169-15-00 Phase I (FiH) 2 countries Recode Therapeutics Inc.
• Evaluation of ELX/TEZ/IVA in Cystic Fibrosis Subjects 12 to Less Than 24 Months of Age Ended
  2023-503230-49-00 Phase III 3 countries Vertex Pharmaceuticals Inc.
• Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Subjects 2 Years and Older Ended
  2024-515606-90-00 Phase III 1 country Vertex Pharmaceuticals Inc.

Showing 1–8 of 8 trials